Variant · Snv
IDH1 R132H
CI-VAR-00003657Explore in graph →NP_005887.2:p.Arg132HisNM_001282386.1:c.395G>AClinVar 156444 CIViC 420 rs121913500
Curated evidence
Evidence by cancer (27 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29670690
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Acute Myeloid Leukemia4 | ||||||||
| IDH1 R132C OR IDH1 R132H | (oncogenic) | Oncogenic | B | Supports Oncogenicity | 3 | submitted | EID12902Popovici-Muller et al. report that IDH1 R132 mutations are gain-of-function alterations that result in production of the oncometabolite D-2-hydroxyglutarate (2-HG). The authors state that elevated 2-H… (full text at CIViC) PMID 29670690 · Popovici-Muller et al., 2018 · Open in CIViC | civic |
| IDH1 R132C OR IDH1 R132H | Ivosidenib | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID12903Popovici-Muller et al. reported preliminary efficacy data from an ongoing phase 1 study of ivosidenib (AG-120) monotherapy in patients with IDH1-mutated malignancies. In patients with relapsed or refr… (full text at CIViC) PMID 29670690 · Popovici-Muller et al., 2018 · Open in CIViC | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available